• Je něco špatně v tomto záznamu ?

Ribociclib plus letrozole versus letrozole alone in patients with de novo HR+, HER2- advanced breast cancer in the randomized MONALEESA-2 trial

J. O'Shaughnessy, K. Petrakova, GS. Sonke, P. Conte, CL. Arteaga, DA. Cameron, LL. Hart, C. Villanueva, E. Jakobsen, JT. Beck, D. Lindquist, F. Souami, S. Mondal, C. Germa, GN. Hortobagyi,

. 2018 ; 168 (1) : 127-134. [pub] 20171121

Jazyk angličtina Země Nizozemsko

Typ dokumentu klinické zkoušky, fáze III, srovnávací studie, časopisecké články, randomizované kontrolované studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc19013008
E-zdroje Online Plný text

NLK ProQuest Central od 1997-01-01 do Před 1 rokem
Medline Complete (EBSCOhost) od 2005-01-01 do Před 1 rokem
Health & Medicine (ProQuest) od 1997-01-01 do Před 1 rokem
Family Health Database (ProQuest) od 1997-01-01 do Před 1 rokem
Public Health Database (ProQuest) od 1997-01-01 do Před 1 rokem

Odkazy

PubMed 29164421
DOI 10.1007/s10549-017-4518-8
Knihovny.cz E-zdroje

PURPOSE: Determine the efficacy and safety of first-line ribociclib plus letrozole in patients with de novo advanced breast cancer. METHODS: Postmenopausal women with HR+ , HER2- advanced breast cancer and no prior systemic therapy for advanced disease were enrolled in the Phase III MONALEESA-2 trial (NCT01958021). Patients were randomized to ribociclib (600 mg/day; 3 weeks-on/1 week-off) plus letrozole (2.5 mg/day; continuous) or placebo plus letrozole until disease progression, unacceptable toxicity, death, or treatment discontinuation. The primary endpoint was investigator-assessed progression-free survival; predefined subgroup analysis evaluated progression-free survival in patients with de novo advanced breast cancer. Secondary endpoints included safety and overall response rate. RESULTS: Six hundred and sixty-eight patients were enrolled, of whom 227 patients (34%; ribociclib plus letrozole vs placebo plus letrozole arm: n = 114 vs. n = 113) presented with de novo advanced breast cancer. Median progression-free survival was not reached in the ribociclib plus letrozole arm versus 16.4 months in the placebo plus letrozole arm in patients with de novo advanced breast cancer (hazard ratio 0.45, 95% confidence interval 0.27-0.75). The most common Grade 3/4 adverse events were neutropenia and leukopenia; incidence rates were similar to those observed in the full MONALEESA-2 population. Ribociclib dose interruptions and reductions in patients with de novo disease occurred at similar frequencies to the overall study population. CONCLUSIONS: Ribociclib plus letrozole improved progression-free survival vs placebo plus letrozole and was well tolerated in postmenopausal women with HR+, HER2- de novo advanced breast cancer.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19013008
003      
CZ-PrNML
005      
20190411093738.0
007      
ta
008      
190405s2018 ne f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s10549-017-4518-8 $2 doi
035    __
$a (PubMed)29164421
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ne
100    1_
$a O'Shaughnessy, Joyce $u Texas Oncology-Baylor Charles A. Sammons Cancer Center and US Oncology Network, 3410 Worth Street, Suite 400, Dallas, TX, 75246, USA. Joyce.OShaughnessy@USOncology.com.
245    10
$a Ribociclib plus letrozole versus letrozole alone in patients with de novo HR+, HER2- advanced breast cancer in the randomized MONALEESA-2 trial / $c J. O'Shaughnessy, K. Petrakova, GS. Sonke, P. Conte, CL. Arteaga, DA. Cameron, LL. Hart, C. Villanueva, E. Jakobsen, JT. Beck, D. Lindquist, F. Souami, S. Mondal, C. Germa, GN. Hortobagyi,
520    9_
$a PURPOSE: Determine the efficacy and safety of first-line ribociclib plus letrozole in patients with de novo advanced breast cancer. METHODS: Postmenopausal women with HR+ , HER2- advanced breast cancer and no prior systemic therapy for advanced disease were enrolled in the Phase III MONALEESA-2 trial (NCT01958021). Patients were randomized to ribociclib (600 mg/day; 3 weeks-on/1 week-off) plus letrozole (2.5 mg/day; continuous) or placebo plus letrozole until disease progression, unacceptable toxicity, death, or treatment discontinuation. The primary endpoint was investigator-assessed progression-free survival; predefined subgroup analysis evaluated progression-free survival in patients with de novo advanced breast cancer. Secondary endpoints included safety and overall response rate. RESULTS: Six hundred and sixty-eight patients were enrolled, of whom 227 patients (34%; ribociclib plus letrozole vs placebo plus letrozole arm: n = 114 vs. n = 113) presented with de novo advanced breast cancer. Median progression-free survival was not reached in the ribociclib plus letrozole arm versus 16.4 months in the placebo plus letrozole arm in patients with de novo advanced breast cancer (hazard ratio 0.45, 95% confidence interval 0.27-0.75). The most common Grade 3/4 adverse events were neutropenia and leukopenia; incidence rates were similar to those observed in the full MONALEESA-2 population. Ribociclib dose interruptions and reductions in patients with de novo disease occurred at similar frequencies to the overall study population. CONCLUSIONS: Ribociclib plus letrozole improved progression-free survival vs placebo plus letrozole and was well tolerated in postmenopausal women with HR+, HER2- de novo advanced breast cancer.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a aminopyridiny $x terapeutické užití $7 D000631
650    _2
$a protokoly protinádorové kombinované chemoterapie $x terapeutické užití $7 D000971
650    _2
$a prsy $x patologie $7 D001940
650    _2
$a nádory prsu $x farmakoterapie $x mortalita $x patologie $7 D001943
650    _2
$a febrilní neutropenie vyvolaná chemoterapií $x epidemiologie $x etiologie $7 D064146
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a incidence $7 D015994
650    _2
$a Kaplanův-Meierův odhad $7 D053208
650    _2
$a letrozol $x terapeutické užití $7 D000077289
650    _2
$a leukopenie $x chemicky indukované $x epidemiologie $7 D007970
650    _2
$a lidé středního věku $7 D008875
650    _2
$a postmenopauza $7 D017698
650    _2
$a doba přežití bez progrese choroby $7 D000077982
650    _2
$a puriny $x terapeutické užití $7 D011687
650    _2
$a receptory pro estrogeny $x metabolismus $7 D011960
650    _2
$a receptory progesteronu $x metabolismus $7 D011980
650    _2
$a kritéria léčebné odpovědi $7 D066066
650    _2
$a časové faktory $7 D013997
655    _2
$a klinické zkoušky, fáze III $7 D017428
655    _2
$a srovnávací studie $7 D003160
655    _2
$a časopisecké články $7 D016428
655    _2
$a randomizované kontrolované studie $7 D016449
700    1_
$a Petrakova, Katarina $u Masaryk Memorial Cancer Institute, Žlutý kopec 543/7, 656 53, Brno, Czech Republic.
700    1_
$a Sonke, Gabe S $u Netherlands Cancer Institute and BOOG Study Center, IJsbaanpad 9, 1076 CV, Amsterdam, The Netherlands.
700    1_
$a Conte, Pierfranco $u University of Padova and Istituto Oncologico Veneto, IRCCS, Via Gattamelata, 64, Padua, Italy.
700    1_
$a Arteaga, Carlos L $u Vanderbilt-Ingram Cancer Center, 1301 Medical Center Dr #1710, Nashville, TN, 37232, USA.
700    1_
$a Cameron, David A $u Edinburgh Cancer Centre, University of Edinburgh, Crewe Rd S, Edinburgh, EH4 2XR, UK.
700    1_
$a Hart, Lowell L $u Sarah Cannon Research Institute, Fort Myers, FL, 33916, USA.
700    1_
$a Villanueva, Cristian $u University Hospital of Besançon, Jean-Minjoz University Hospital, 3 Boulevard Alexandre Fleming, 25000, Besançon, France.
700    1_
$a Jakobsen, Erik $u Lillebaelt Hospital, Kabbeltoft 25, 7100, Vejle, Denmark.
700    1_
$a Beck, Joseph T $u Highlands Oncology Group, 3232 N Northhills Blvd, Fayetteville, AR, 72703, USA.
700    1_
$a Lindquist, Deborah $u Arizona Oncology, US Oncology Network, 3700 W State Rte 89A, Sedona, AZ, 86336, USA.
700    1_
$a Souami, Farida $u Novartis Pharma AG, Fabrikstrasse 2, 4056, Basel, Switzerland.
700    1_
$a Mondal, Shoubhik $u Novartis Pharmaceuticals Corporation, 1 Health Plaza, East Hanover, NJ, 07936, USA.
700    1_
$a Germa, Caroline $u Novartis Pharmaceuticals Corporation, 1 Health Plaza, East Hanover, NJ, 07936, USA.
700    1_
$a Hortobagyi, Gabriel N $u University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA.
773    0_
$w MED00009361 $t Breast cancer research and treatment $x 1573-7217 $g Roč. 168, č. 1 (2018), s. 127-134
856    41
$u https://pubmed.ncbi.nlm.nih.gov/29164421 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20190405 $b ABA008
991    __
$a 20190411093755 $b ABA008
999    __
$a ok $b bmc $g 1392318 $s 1051313
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 168 $c 1 $d 127-134 $e 20171121 $i 1573-7217 $m Breast cancer research and treatment $n Breast Cancer Res Treat $x MED00009361
LZP    __
$a Pubmed-20190405

Najít záznam

Citační ukazatele

Možnosti archivace